Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206

Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli

(2020) Yawei Zhang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)

(2019) Ana C Gales et al.   Open Forum Infectious Diseases

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

(2019) Chau-Chyun Sheu et al.   Frontiers in Microbiology

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

(2019) Brian T. Tsuji et al.   PHARMACOTHERAPY

Carbapenem-resistant Acinetobacterbaumannii: in pursuitof an effective treatment

(2019) Evangelia-Theophano Piperaki et al.   CLINICAL MICROBIOLOGY AND INFECTION

How should we treat acinetobacter pneumonia?

(2019) Rosario Amaya-Villar et al.   Current Opinion in Critical Care

A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features

(2019) Baris Boral et al.   Annals of Clinical Microbiology and Antimicrobials

Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206

(2019) Pamela Brown et al.   ACS Infectious Diseases

Infections Due to Acinetobacter baumannii in the ICU: Treatment Options

(2017) George Zhanel et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

(2017) Bin Cai et al.   Open Forum Infectious Diseases

Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?

(2016) Alexandre P. Zavascki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges

(2016) Darren Wong et al.   CLINICAL MICROBIOLOGY REVIEWS

Emergence of antimicrobial resistance among Acinetobacter species

(2016) Nina M. Clark et al.   Current Opinion in Critical Care

Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

(2016) Abi Jenkins et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies

(2016) Yu Zhang et al.   Emerging Microbes & Infections

Combination Therapy for Extreme Drug–Resistant Acinetobacter baumannii

(2015) Brad Spellberg et al.   CRITICAL CARE MEDICINE

Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia

(2015) Aristine Cheng et al.   CRITICAL CARE MEDICINE

Secular trends inAcinetobacter baumanniiresistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study

(2015) Marya D. Zilberberg et al.   Journal of Hospital Medicine

Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis

(2013) E.V. Lemos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010

(2012) Dawn M. Sievert et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

The Future of Aminoglycosides: The End or Renaissance?

(2010) Jacob L. Houghton  et al.   CHEMBIOCHEM